Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism, a condition in which the thyroid gland produces too much of the hormone thyroxine. It is named after Robert J. Graves, an Irish physician who first described the disorder in 1835. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Symptoms of Graves’ disease can include weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland.
Graves’ disease is an autoimmune disorder in which the body’s immune system mistakenly attacks the thyroid gland. This causes the thyroid gland to produce too much of the hormone thyroxine. Too much thyroxine can lead to a number of symptoms, including weight loss, fatigue, anxiety, irritability, heat intolerance, and an enlarged thyroid gland (goiter). Graves’ disease is the most common form of hyperthyroidism, and it is estimated to affect approximately 1 in 200 people.
The exact cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Studies have shown that people with Graves’ disease are more likely to have certain genetic variations, which may increase their risk of developing the disorder. Additionally, environmental factors such as stress, smoking, and certain medications may increase the risk of developing Graves’ disease.
Graves’ disease is typically diagnosed based on a physical examination and a review of the patient’s medical history. A doctor may also order blood tests to measure levels of thyroid hormones and antibodies associated with Graves’ disease. An imaging test such as an ultrasound or CT scan may be used to look for an enlarged thyroid gland.
Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. Medications such as antithyroid drugs, beta-blockers, and radioactive iodine can be used to reduce the production of thyroxine. Surgery to remove part or all of the thyroid gland is usually recommended for people with severe symptoms or those who do not respond to medications.
Graves’ disease is an autoimmune disorder that affects the thyroid gland. It is the most common form of hyperthyroidism and it is estimated to affect approximately 1 in 200 people. The cause of Graves’ disease is unknown, although it is believed to be linked to genetic and environmental factors. Treatment for Graves’ disease typically involves medications to reduce thyroxine levels and surgery to remove part or all of the thyroid gland. It is important for doctors to be aware of the signs and symptoms of Graves’ disease in order to properly diagnose and treat the disorder.
1.
The use of biomarkers in the treatment of breast lumps is at a crossroads.
2.
According to JAMA, 5 alpha-reductase inhibitors are not significantly linked to prostate cancer mortality.
3.
How Do Younger People Fare With Stool Tests for CRC Screening?
4.
Dual Targeted CAR-T Yields 99% Response Rate in Pediatric ALL
5.
Is It Really Cancer? More Concerns About Accelerated Approval; Metformin and Cancer
1.
How Parvovirus B19 Affects Pregnant Women and Their Unborn Babies
2.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
3.
Introduction to Immune Thrombocytopenic Purpura
4.
Unveiling the Chadwick Sign: A Revolutionary New Tool for Detecting Early Signs of Cancer
5.
The Different Types of Cysts and Why They Occur: Insights from a Dermatologist
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Current Cancer Scenario in India- Importance of Genomic Testing & Advancement in Diagnosis and Treatment
2.
Preventing Blood Clots: The Importance of Venous Thromboembolism Management
3.
A Panel Discussion on Clinical Trial End Point for Tumor With PPS > 12 months
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation